CL2004001078A1 - Compuestos derivados de imidazol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto de miocardio agudo, trastornos - Google Patents
Compuestos derivados de imidazol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto de miocardio agudo, trastornosInfo
- Publication number
- CL2004001078A1 CL2004001078A1 CL200401078A CL2004001078A CL2004001078A1 CL 2004001078 A1 CL2004001078 A1 CL 2004001078A1 CL 200401078 A CL200401078 A CL 200401078A CL 2004001078 A CL2004001078 A CL 2004001078A CL 2004001078 A1 CL2004001078 A1 CL 2004001078A1
- Authority
- CL
- Chile
- Prior art keywords
- factor
- thrombes
- miochard
- infratement
- fibrinolisis
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 108010074860 Factor Xa Proteins 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011305A EP1479676A1 (en) | 2003-05-19 | 2003-05-19 | Benzimidazole-derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2004001078A1 true CL2004001078A1 (es) | 2005-04-08 |
Family
ID=33040952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200401078A CL2004001078A1 (es) | 2003-05-19 | 2004-05-17 | Compuestos derivados de imidazol condensados, inhibidores del factor xa y/o del factor vlla; composicion farmaceutica; proceso de preparacion; y su uso para tratar fibrinolisis, la formacion anormal de trombos, infarto de miocardio agudo, trastornos |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP1479676A1 (https=) |
| JP (1) | JP4658940B2 (https=) |
| KR (1) | KR20060014056A (https=) |
| CN (2) | CN100484935C (https=) |
| AR (1) | AR045683A1 (https=) |
| AT (1) | ATE474838T1 (https=) |
| AU (1) | AU2004238497B2 (https=) |
| BR (1) | BRPI0410446A (https=) |
| CA (1) | CA2526065A1 (https=) |
| CL (1) | CL2004001078A1 (https=) |
| CR (1) | CR8087A (https=) |
| DE (1) | DE602004028240D1 (https=) |
| EC (1) | ECSP056178A (https=) |
| MA (1) | MA27798A1 (https=) |
| MX (1) | MXPA05012231A (https=) |
| NO (1) | NO20055910L (https=) |
| NZ (1) | NZ543670A (https=) |
| OA (1) | OA13168A (https=) |
| PA (1) | PA8603501A1 (https=) |
| PE (1) | PE20050198A1 (https=) |
| RS (1) | RS20050856A (https=) |
| RU (1) | RU2346944C2 (https=) |
| SA (1) | SA04250196B1 (https=) |
| TN (1) | TNSN05297A1 (https=) |
| TW (1) | TW200503696A (https=) |
| UA (1) | UA82100C2 (https=) |
| UY (1) | UY28324A1 (https=) |
| WO (1) | WO2004101553A1 (https=) |
| ZA (1) | ZA200508151B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10342570A1 (de) * | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| EP1742637A4 (en) | 2004-04-23 | 2011-06-08 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| US9840489B2 (en) * | 2013-12-20 | 2017-12-12 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Piperidine carboxamide compound, preparation method, and usage thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1377642A (en) * | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4897401A (en) * | 1987-06-19 | 1990-01-30 | Janssen Pharmaceutical N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases |
| DE3828537A1 (de) * | 1988-08-23 | 1990-03-01 | Basf Ag | Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material |
| JPH0324609A (ja) * | 1989-06-21 | 1991-02-01 | Mitsuba Electric Mfg Co Ltd | Ｉ／ｏ用バッファｉｃ |
| JPH03184043A (ja) * | 1989-12-14 | 1991-08-12 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| KR100190299B1 (ko) * | 1990-07-19 | 1999-06-01 | 디르크 반테 | 신규한 옥사졸릴 유도체 |
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| SI9520096A (sl) * | 1994-09-30 | 1998-04-30 | Pfizer Inc. | Derivati 2,7-substituiranega oktahidro-1H-pirido /1,2-a/ pirazina |
| JPH08208640A (ja) * | 1995-02-06 | 1996-08-13 | Nisshin Flour Milling Co Ltd | ベンズイミダゾール誘導体およびそれを含有する心不全治療薬 |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| JPH09124609A (ja) * | 1995-11-07 | 1997-05-13 | Nissan Chem Ind Ltd | ベンズイミダゾール誘導体 |
| JPH10182459A (ja) * | 1996-12-26 | 1998-07-07 | Otsuka Pharmaceut Co Ltd | ｃＧＭＰ分解酵素阻害剤 |
| UA62972C2 (en) * | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| PL343424A1 (en) * | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
| WO2004022060A2 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
-
2003
- 2003-05-19 EP EP03011305A patent/EP1479676A1/en not_active Withdrawn
-
2004
- 2004-05-03 PE PE2004000446A patent/PE20050198A1/es not_active Application Discontinuation
- 2004-05-05 EP EP04731162A patent/EP1636216B1/en not_active Expired - Lifetime
- 2004-05-05 JP JP2006529739A patent/JP4658940B2/ja not_active Expired - Fee Related
- 2004-05-05 BR BRPI0410446-3A patent/BRPI0410446A/pt not_active IP Right Cessation
- 2004-05-05 UA UAA200512138A patent/UA82100C2/uk unknown
- 2004-05-05 RU RU2005139555/04A patent/RU2346944C2/ru not_active IP Right Cessation
- 2004-05-05 CN CNB2004800139377A patent/CN100484935C/zh not_active Expired - Fee Related
- 2004-05-05 RS YUP-2005/0856A patent/RS20050856A/sr unknown
- 2004-05-05 MX MXPA05012231A patent/MXPA05012231A/es active IP Right Grant
- 2004-05-05 DE DE602004028240T patent/DE602004028240D1/de not_active Expired - Lifetime
- 2004-05-05 AT AT04731162T patent/ATE474838T1/de not_active IP Right Cessation
- 2004-05-05 AU AU2004238497A patent/AU2004238497B2/en not_active Expired - Fee Related
- 2004-05-05 OA OA1200500322A patent/OA13168A/en unknown
- 2004-05-05 WO PCT/EP2004/004750 patent/WO2004101553A1/en not_active Ceased
- 2004-05-05 CN CNA2007101491602A patent/CN101139346A/zh active Pending
- 2004-05-05 CA CA002526065A patent/CA2526065A1/en not_active Abandoned
- 2004-05-05 KR KR1020057022122A patent/KR20060014056A/ko not_active Ceased
- 2004-05-05 NZ NZ543670A patent/NZ543670A/en unknown
- 2004-05-17 TW TW093113795A patent/TW200503696A/zh unknown
- 2004-05-17 AR ARP040101695A patent/AR045683A1/es not_active Application Discontinuation
- 2004-05-17 CL CL200401078A patent/CL2004001078A1/es unknown
- 2004-05-19 UY UY28324A patent/UY28324A1/es unknown
- 2004-05-19 PA PA20048603501A patent/PA8603501A1/es unknown
- 2004-06-30 SA SA04250196A patent/SA04250196B1/ar unknown
-
2005
- 2005-10-10 ZA ZA200508151A patent/ZA200508151B/xx unknown
- 2005-11-08 MA MA28587A patent/MA27798A1/fr unknown
- 2005-11-11 CR CR8087A patent/CR8087A/es not_active Application Discontinuation
- 2005-11-18 TN TNP2005000297A patent/TNSN05297A1/en unknown
- 2005-11-18 EC EC2005006178A patent/ECSP056178A/es unknown
- 2005-12-13 NO NO20055910A patent/NO20055910L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2007002169A1 (es) | Compuestos derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso del compuesto para prevenir o tratar la inflamacion, trastornos urologicos, gastrointestina | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
| BR0112292A (pt) | Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto | |
| NO20055316D0 (no) | Nye heterocykliske forbindelser som er nyttige ved behandling av inflammatoriske og allergiske forstyrrelser, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger som inneholder slike | |
| BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
| EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
| NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| WO2008116139A3 (en) | N-heterocyclic compounds useful as inhibitors of janus kinases | |
| CL2003002683A1 (es) | Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos, | |
| CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
| CL2003002353A1 (es) | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic | |
| IL184148A (en) | History of triazole is claimed as oxytocin antagonists, their pharmacological preparations and their use in the preparation of drugs for the treatment of disorders in which the inhibition of oxytocin gives a beneficial effect | |
| WO2007084841A3 (en) | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
| CL2008003301A1 (es) | Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras. | |
| IL191310A (en) | A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| BRPI0815696A2 (pt) | composto derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, metódo para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr e uso destes compostos. | |
| JP2007506758A5 (ja) | ４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ−プロポキシ）−安息香酸誘導体および線溶系の障害、血栓症の治療用のｐａｉ−１阻害剤としての関連化合物 |